Incyte annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Incyte Revenue Growth & History (INCY)
Incyte reported $5.14B in revenue for fiscal 2025, an increase of 21.22% from the previous fiscal year.
View full Incyte company overviewIncyte annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.14B | $900.0M | +21.22% |
| 2024 | 2024-12-31 | $4.24B | $545.6M | +14.76% |
| 2023 | 2023-12-31 | $3.70B | $301.0M | +8.87% |
| 2022 | 2022-12-31 | $3.39B | $408.4M | +13.67% |
| 2021 | 2021-12-31 | $2.99B | $319.6M | +11.98% |
| 2020 | 2020-12-31 | $2.67B | $507.9M | +23.53% |
| 2019 | 2019-12-31 | $2.16B | $276.9M | +14.71% |
| 2018 | 2018-12-31 | $1.88B | $345.7M | +22.50% |
| 2017 | 2017-12-31 | $1.54B | $430.5M | +38.93% |
| 2016 | 2016-12-31 | $1.11B | $352.0M | +46.70% |
| 2015 | 2015-12-31 | $753.8M | $242.3M | +47.36% |
| 2014 | 2014-12-31 | $511.5M | $156.5M | +44.10% |
| 2013 | 2013-12-31 | $354.9M | $57.9M | +19.49% |
| 2012 | 2012-12-31 | $297.1M | $202.6M | +214.50% |
| 2011 | 2011-12-31 | $94.5M | −$75.4M | −44.40% |
| 2010 | 2010-12-31 | $169.9M | $160.6M | +1733.55% |
| 2009 | 2009-12-31 | $9.3M | — | — |
Incyte quarterly revenue
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.67B | $458.5M | +37.72% |
| Q1 2026 | 2026-03-31 | $1.27B | $219.8M | +20.87% |
| Q4 2025 | 2025-12-31 | $1.51B | $328.1M | +27.84% |
| Q3 2025 | 2025-09-30 | $1.37B | $228.1M | +20.05% |
| Q2 2025 | 2025-06-30 | $1.22B | $171.8M | +16.46% |
| Q1 2025 | 2025-03-31 | $1.05B | $172.0M | +19.53% |
| Q4 2024 | 2024-12-31 | $1.18B | $165.4M | +16.32% |
| Q3 2024 | 2024-09-30 | $1.14B | $218.8M | +23.81% |
| Q2 2024 | 2024-06-30 | $1.04B | $89.1M | +9.34% |
| Q1 2024 | 2024-03-31 | $880.9M | $72.2M | +8.93% |
| Q4 2023 | 2023-12-31 | $1.01B | $86.6M | +9.35% |
| Q3 2023 | 2023-09-30 | $919.0M | $95.7M | +11.63% |
| Q2 2023 | 2023-06-30 | $954.6M | $43.2M | +4.74% |
| Q1 2023 | 2023-03-31 | $808.7M | $75.4M | +10.29% |
| Q4 2022 | 2022-12-31 | $926.7M | $63.8M | +7.40% |
| Q3 2022 | 2022-09-30 | $823.3M | $10.3M | +1.27% |
| Q2 2022 | 2022-06-30 | $911.4M | $205.7M | +29.15% |
| Q1 2022 | 2022-03-31 | $733.2M | $128.5M | +21.25% |
| Q4 2021 | 2021-12-31 | $862.9M | $73.3M | +9.29% |
| Q3 2021 | 2021-09-30 | $813.0M | $192.3M | +30.99% |
| Q2 2021 | 2021-06-30 | $705.7M | $17.7M | +2.57% |
| Q1 2021 | 2021-03-31 | $604.7M | $36.2M | +6.37% |
| Q4 2020 | 2020-12-31 | $789.5M | $210.1M | +36.27% |
| Q3 2020 | 2020-09-30 | $620.6M | $69.1M | +12.52% |
| Q2 2020 | 2020-06-30 | $688.0M | $158.1M | +29.84% |
| Q1 2020 | 2020-03-31 | $568.5M | $70.7M | +14.19% |
| Q4 2019 | 2019-12-31 | $579.4M | $51.0M | +9.65% |
| Q3 2019 | 2019-09-30 | $551.6M | $101.9M | +22.66% |
| Q2 2019 | 2019-06-30 | $529.9M | $8.4M | +1.61% |
| Q1 2019 | 2019-03-31 | $497.9M | $115.6M | +30.23% |
| Q4 2018 | 2018-12-31 | $528.4M | $84.2M | +18.97% |
| Q3 2018 | 2018-09-30 | $449.7M | $68.1M | +17.86% |
| Q2 2018 | 2018-06-30 | $521.5M | $195.1M | +59.76% |
| Q1 2018 | 2018-03-31 | $382.3M | −$1.8M | −0.47% |
| Q4 2017 | 2017-12-31 | $444.2M | $117.7M | +36.04% |
| Q3 2017 | 2017-09-30 | $381.5M | $112.1M | +41.59% |
| Q2 2017 | 2017-06-30 | $326.4M | $80.2M | +32.55% |
| Q1 2017 | 2017-03-31 | $384.1M | $120.6M | +45.78% |
| Q4 2016 | 2016-12-31 | $326.5M | $82.6M | +33.88% |
| Q3 2016 | 2016-09-30 | $269.5M | $81.9M | +43.63% |
| Q2 2016 | 2016-06-30 | $246.3M | $83.3M | +51.11% |
| Q1 2016 | 2016-03-31 | $263.5M | $104.2M | +65.41% |
| Q4 2015 | 2015-12-31 | $243.9M | $119.9M | +96.72% |
| Q3 2015 | 2015-09-30 | $187.6M | −$10.5M | −5.32% |
| Q2 2015 | 2015-06-30 | $163.0M | $63.4M | +63.67% |
| Q1 2015 | 2015-03-31 | $159.3M | $69.5M | +77.38% |
| Q4 2014 | 2014-12-31 | $124.0M | $26.9M | +27.71% |
| Q3 2014 | 2014-09-30 | $198.1M | $113.0M | +132.78% |
| Q2 2014 | 2014-06-30 | $99.6M | −$2.1M | −2.06% |
| Q1 2014 | 2014-03-31 | $89.8M | $18.7M | +26.33% |
| Q4 2013 | 2013-12-31 | $97.1M | −$16.8M | −14.73% |
| Q3 2013 | 2013-09-30 | $85.1M | $24.6M | +40.72% |
| Q2 2013 | 2013-06-30 | $101.7M | $15.1M | +17.49% |
| Q1 2013 | 2013-03-31 | $71.1M | $34.9M | +96.46% |
| Q4 2012 | 2012-12-31 | $113.8M | $85.0M | +294.08% |
| Q3 2012 | 2012-09-30 | $60.5M | $43.7M | +260.46% |
| Q2 2012 | 2012-06-30 | $86.5M | $69.7M | +414.79% |
| Q1 2012 | 2012-03-31 | $36.2M | $4.2M | +13.15% |
| Q4 2011 | 2011-12-31 | $28.9M | −$57.0M | −66.36% |
| Q3 2011 | 2011-09-30 | $16.8M | −$90,000 | −0.53% |
| Q2 2011 | 2011-06-30 | $16.8M | −$33.0M | −66.27% |
| Q1 2011 | 2011-03-31 | $32.0M | $14.7M | +84.94% |
| Q4 2010 | 2010-12-31 | $85.9M | — | — |
| Q3 2010 | 2010-09-30 | $16.9M | — | — |
| Q2 2010 | 2010-06-30 | $49.8M | — | — |
| Q1 2010 | 2010-03-31 | $17.3M | — | — |
Incyte revenue growth trends
Over the last five reported fiscal years, revenue grew from $2.67B to $5.14B, a compound annual growth rate of 14.03%. Incyte's latest reported quarter, Q2 2026, generated $1.67B in revenue, an increase of 37.72% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Incyte source filings ↗Community posts
Incyte expands Opzelura partnership to Australia
Incyte ($INCY) expanded its partnership with Specialised Therapeutics to include Opzelura in Australia. The arrangement assigns local regulatory submissions, medical affairs, marketing and distribution responsibilities to the partner, while ...
